How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
Blood
; 140(7): 673-684, 2022 08 18.
Article
in English
| MEDLINE | ID: covidwho-1916904
ABSTRACT
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation (HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have a higher risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Compared with the general population, these patients have suboptimal humoral responses to COVID-19 vaccines and subsequently increased risk for breakthrough infections, underscoring the need for additional therapies, including pre- and postexposure prophylaxis, to attenuate clinical progression to severe COVID-19. Therapies for COVID-19 are mostly available for adults and in the inpatient and outpatient settings. Selection and administration of the best treatment options are based on host factors; virus factors, including circulating SARS-CoV-2 variants; and therapeutic considerations, including the clinical efficacy, availability, and practicality of treatment and its associated side effects, including drug-drug interactions. In this paper, we discuss how we approach managing COVID-19 in patients with hematologic malignancies and recipients of HCT and cell therapy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19
Type of study:
Prognostic study
Topics:
Long Covid
/
Vaccines
/
Variants
Limits:
Adult
/
Humans
Language:
English
Journal:
Blood
Year:
2022
Document Type:
Article
Affiliation country:
Blood.2022016089
Similar
MEDLINE
...
LILACS
LIS